Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 15/20 | 0.54 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | GCK | P35557 | 1/20 | 0.45 |
| ▸ | GCKR | Q14397 | 1/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL427501 | 1.00 | HSD11B1 (0.54) | HSD11B1KIF11GCKGCKRNR1H3 | |
| SCHEMBL20956389 | 1.00 | HSD11B1 (0.54) | HSD11B1KIF11GCKGCKRNR1H3 | |
| Hydrochloric Acid SCHEMBL20956393 | 0.98 | HSD11B1 (0.53) | HSD11B1KIF11GCKGCKRNR1H3 | |
| Hydrochloric Acid SCHEMBL20956392 | 0.98 | HSD11B1 (0.53) | HSD11B1KIF11GCKGCKRNR1H3 | |
| Hydrochloric Acid SCHEMBL19179710 | 0.98 | HSD11B1 (0.53) | HSD11B1KIF11GCKGCKRNR1H3 | |
| SCHEMBL10165226 | 0.88 | HSD11B1 (0.59) | HSD11B1NR1H3 | |
| SCHEMBL13917764 | 0.85 | ALDH1A1 (0.48) | HSD11B1KIF11NPC1ALDH1A1MAPT | |
| SCHEMBL25753451 | 0.81 | HSD11B1 (0.53) | HSD11B1NR1H3 | |
| SCHEMBL15459955 | 0.81 | HSD11B1 (0.53) | HSD11B1NR1H3 | |
| SCHEMBL5530921 | 0.79 | MLYCD (0.52) | HSD11B1NR1H3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054339-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS INHIBITORS OF KIT | ARCUS BIOSCIENCES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| EP-3210969-B1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO (JP) | 2021-04-28 | — | — | EP | disclosed |
| CN-107108485-B | KCNQ 2-5 channel activator | 小野药品工业株式会社 | 2020-06-12 | — | — | CN | disclosed |
| US-10676438-B2 | KCNQ2-5 channel activator | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-09 | — | — | US | disclosed |
| US-20200157050-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| US-10570093-B2 | — | — | 2020-02-25 | — | — | US | disclosed |
| US-10196358-B2 | KCNQ2-5 channel activator | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-02-05 | — | — | US | disclosed |
| US-20180346422-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-12-06 | — | — | US | disclosed |
| US-20170334855-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-23 | — | — | US | disclosed |
| US-9809544-B2 | KCNQ2-5 channel activator | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-07 | — | — | US | disclosed |
| EP-3210969-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO Pharmaceutical Co., Ltd. (JP) | 2017-08-30 | — | — | EP | disclosed |
| CN-107108485-A | KCNQ 2-5 channel activator | 小野药品工业株式会社 | 2017-08-29 | — | — | CN | disclosed |
| US-20170217888-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD (JP) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570093-B2 | — | KCNQ5, KCNQ2, KCNQ1 | HSD11B1 2566/4885KIF11 1638/4885GCK 1950/4885 |
| US-20170334855-A1 | KCNQ2-5 CHANNEL ACTIVATOR | KCNQ5, KCNQ2, KCNQ1 | HSD11B1 4314/4885KIF11 2061/4885GCK 972/4885 |
| US-20170217888-A1 | KCNQ2-5 CHANNEL ACTIVATOR | KCNQ5, KCNQ2, KCNQ1 | HSD11B1 4314/4885KIF11 2061/4885GCK 972/4885 |
| US-20200157050-A1 | KCNQ2-5 CHANNEL ACTIVATOR | KCNQ5, KCNQ2, KCNQ1 | HSD11B1 4314/4885KIF11 2061/4885GCK 972/4885 |
| US-20180346422-A1 | KCNQ2-5 CHANNEL ACTIVATOR | KCNQ5, KCNQ2, KCNQ1 | HSD11B1 4314/4885KIF11 2061/4885GCK 972/4885 |
| US-10676438-B2 | KCNQ2-5 channel activator | KCNQ5, KCNQ2, KCNQ1 | HSD11B1 4314/4885KIF11 2061/4885GCK 972/4885 |
| US-10196358-B2 | KCNQ2-5 channel activator | KCNQ5, KCNQ2, KCNQ1 | HSD11B1 4314/4885KIF11 2061/4885GCK 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.